Skip to main content
Clinical Trials/NCT04116814
NCT04116814
Unknown
N/A

High Resolution Imaging of Retinal Vessels as a Biomarker of Cardiovascular Disease in Patients With Renal Insufficiency - (IRIR)

Ramsay Générale de Santé1 site in 1 country83 target enrollmentApril 21, 2018

Overview

Phase
N/A
Intervention
Not specified
Conditions
Retinal Imaging
Sponsor
Ramsay Générale de Santé
Enrollment
83
Locations
1
Primary Endpoint
Predictibilty of WLR
Last Updated
6 years ago

Overview

Brief Summary

The objectives are to better understand, in the dialysis patient, the relationships between microvascular morphometry and cardiovascular events, survival, arterial hypertension, the pathology responsible for renal failure, the age of dialysis and metabolic parameters.

The investigator team also want to better understand the relationship between the diameter of small arteries and parameters such as hypertension, the pathology that causes kidney failure, the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes, BNP, lipid balance, phosphocalcic balance).

Detailed Description

The cardiovascular morbidity of a dialysis patient is 10 times higher than that of a subject in the general population. The patient with renal insufficiency is therefore at high cardiovascular risk. An increase in the wall-to-lumen ratio (WLR) is an early sign of microvascular damage, predictive of the risk of a cardiovascular event. The benefits of WLR measurement are therefore at the level of both the diagnosis and prognosis of vascular disease. Recently, a fundus camera coupled with an adaptive optics system has been able to measure for the first time in vivo non-invasively and reproducibly the wall thickness of the small arteries of the retina, and therefore the WLR, among other biomarkers relating to microvascular remodelling. Studies in hypertension have confirmed that the rtX1 camera allows reliable and reproducible measurements of the WLR. The main aim of our study is to evaluate the value of the WLR as a biomarker of the risk of cardiovascular morbidity and mortality in patients with renal insufficiency. The objectives are to better understand, in the dialysis patient, the relationships between microvascular morphometry and cardiovascular events, survival, arterial hypertension, the pathology responsible for renal failure, the age of dialysis and metabolic parameters. The investigator team also want to better understand the relationship between the diameter of small arteries and parameters such as hypertension, the pathology that causes kidney failure, the age of dialysis, the use of VKA or EPO, metabolic parameters (HbA1c, NFS, reticulocytes, BNP, lipid balance, phosphocalcic balance).

Registry
clinicaltrials.gov
Start Date
April 21, 2018
End Date
March 31, 2022
Last Updated
6 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with renal insufficiency: waiting for management (dialysis or transplant), during dialysis or after a kidney transplant followed in the nephrology department of the Saint Martin clinic.
  • First examination in adaptive optics giving a usable result (possibility of measuring the WLR)
  • Affiliate or beneficiary of a social security scheme
  • Patient having given their free and informed consent

Exclusion Criteria

  • Protected patients: adults under guardianship, trusteeship or other legal protection, deprived of liberty by judicial or administrative decision, hospitalised without consent.
  • Pregnant, lactating or parturient women.

Outcomes

Primary Outcomes

Predictibilty of WLR

Time Frame: 3 years

The primary endpoint is time to event (cardiovascular events or death) in months, assessed by survival analysis.

Secondary Outcomes

  • WLR associated biomarker(3 years)

Study Sites (1)

Loading locations...

Similar Trials